Douglas, S. R., Thomas, S. M., van den Bruele, A. B., Wang, T., Parrish, K., Rosenberger, L. H., … Chiba, A. (2025). Rate of neoadjuvant endocrine therapy use in estrogen receptor positive breast cancer before and after Covid-19. In ANNALS OF SURGICAL ONCOLOGY (Vol. 32, pp. S196–S196).

Douglas, Sasha R., Samantha M. Thomas, Astrid Botty van den Bruele, Ton Wang, Kendra Parrish, Laura H. Rosenberger, Jennifer K. Plichta, Maggie L. Dinome, and Akiko Chiba. “Rate of neoadjuvant endocrine therapy use in estrogen receptor positive breast cancer before and after Covid-19.” In ANNALS OF SURGICAL ONCOLOGY, 32:S196–S196, 2025.

Douglas SR, Thomas SM, van den Bruele AB, Wang T, Parrish K, Rosenberger LH, et al. Rate of neoadjuvant endocrine therapy use in estrogen receptor positive breast cancer before and after Covid-19. In: ANNALS OF SURGICAL ONCOLOGY. 2025. p. S196–S196.

Douglas, Sasha R., et al. “Rate of neoadjuvant endocrine therapy use in estrogen receptor positive breast cancer before and after Covid-19.” ANNALS OF SURGICAL ONCOLOGY, vol. 32, 2025, pp. S196–S196.

Douglas SR, Thomas SM, van den Bruele AB, Wang T, Parrish K, Rosenberger LH, Plichta JK, Dinome ML, Chiba A. Rate of neoadjuvant endocrine therapy use in estrogen receptor positive breast cancer before and after Covid-19. ANNALS OF SURGICAL ONCOLOGY. 2025. p. S196–S196.